VYNE Therapeutics (NASDAQ:VYNE) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of VYNE Therapeutics (NASDAQ:VYNE) from a sell rating to a hold rating in a research note issued to investors on Friday morning.

Separately, HC Wainwright lowered their price target on shares of VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating on the stock in a research report on Friday, April 25th.

VYNE Therapeutics Price Performance

Shares of VYNE opened at $0.97 on Friday. VYNE Therapeutics has a 1 year low of $0.95 and a 1 year high of $4.30. The stock’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $2.23. The firm has a market cap of $14.68 million, a PE ratio of -1.12 and a beta of 1.76.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.09. The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.05 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. Sell-side analysts anticipate that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VYNE Therapeutics

Hedge funds have recently made changes to their positions in the stock. DAFNA Capital Management LLC bought a new stake in shares of VYNE Therapeutics during the first quarter valued at about $1,005,000. Acorn Capital Advisors LLC purchased a new position in VYNE Therapeutics during the fourth quarter valued at approximately $1,531,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in VYNE Therapeutics during the 4th quarter worth approximately $823,000. Adage Capital Partners GP L.L.C. increased its holdings in VYNE Therapeutics by 123.3% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 344,134 shares of the company’s stock worth $544,000 after acquiring an additional 190,000 shares during the period. Finally, Exome Asset Management LLC lifted its stake in VYNE Therapeutics by 30.9% in the 1st quarter. Exome Asset Management LLC now owns 462,801 shares of the company’s stock worth $731,000 after purchasing an additional 109,367 shares in the last quarter. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.